EP1693045A1 - Production de formes posologiques à partir de substances actives fondues - Google Patents

Production de formes posologiques à partir de substances actives fondues Download PDF

Info

Publication number
EP1693045A1
EP1693045A1 EP05003457A EP05003457A EP1693045A1 EP 1693045 A1 EP1693045 A1 EP 1693045A1 EP 05003457 A EP05003457 A EP 05003457A EP 05003457 A EP05003457 A EP 05003457A EP 1693045 A1 EP1693045 A1 EP 1693045A1
Authority
EP
European Patent Office
Prior art keywords
release
melt
films
film
release films
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05003457A
Other languages
German (de)
English (en)
Inventor
Jörg Rosenberg
Norbert Steiger
Harald Hach
Jörg Breitenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Priority to EP05003457A priority Critical patent/EP1693045A1/fr
Priority to JP2007555537A priority patent/JP2008529852A/ja
Priority to PCT/EP2006/001475 priority patent/WO2006087218A1/fr
Priority to US11/884,521 priority patent/US20090050262A1/en
Priority to ES06707060.7T priority patent/ES2445828T3/es
Priority to DK06707060.7T priority patent/DK1848394T3/da
Priority to EP06707060.7A priority patent/EP1848394B1/fr
Priority to CA2598168A priority patent/CA2598168C/fr
Publication of EP1693045A1 publication Critical patent/EP1693045A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/16—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using pocketed rollers, e.g. two co-operating pocketed rollers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2200/00—General characteristics or adaptations
    • A61J2200/20—Extrusion means, e.g. for producing pharmaceutical forms

Definitions

  • the present invention is a process for the preparation of dosage forms from a drug-containing melt.
  • WO 9707786 describes the use of lipids as an aid in the preparation of solid dosage forms by the melt extrusion process. Between 0.1-10 wt .-% lipids are added to the extrusion mixture as a mold release agent.
  • DE 4446467 describes a process for the production of lenticular tablets by melt calendering. It is referred to in this document that molding rolls can be used, which are provided with a release agent.
  • a release agent for example, a silicone varnish is suitable.
  • EP 0358105 describes a method for shaping extrudate masses. Here are two elastic bands with opposite recesses, which determine the tablet shape used.
  • WO 9619963 describes a process for the production of coated tablets by melt calendering, in which the active substance-containing melt is introduced into the calender forming rolls between two films of the wrapping material.
  • the invention is based on the object to provide a universally applicable method that allows the formation of active ingredient-containing melts without the problems occurring by sticking the melt on or in the mold.
  • the present invention relates to a process in which two release films are brought together in a defined region, an active-substance-containing melt is introduced between the release films so that a pocket for receiving a portion of the melt is formed in at least one of the release films and the release films are separated from one another to demold the portion.
  • one brings the release films in the gap of two counter-rotating forming rollers to each other, of which has at least one wells into which the release film can be pressed to form pockets.
  • both forming rollers on their surface on opposite recesses into which the release films can be pressed to form pockets are particularly preferably, both forming rollers on their surface on opposite recesses into which the release films can be pressed to form pockets.
  • the release film is deformed by the introduced into the trough-shaped space between the forming rollers melt and pressed to the surfaces of the wells.
  • the release film prevents direct contact of the melt with the roll surface, so that any adhesion / adhesion of the melt to the surface of the roll can be excluded.
  • the thickness of the release films used is generally in the range of 0.05 to 1.6 mm, preferably 0.1 to 1 mm and particularly preferably 0.1 to 0.5 mm.
  • the release films of an elastically deformable material since in this case by the relaxation of the release film when leaving the nip, a force occurs, which pushes the molding out of the cavity, so practically ejects the molding.
  • release films with low or negligible elasticity is preferred.
  • the formation of the pockets in the release films can be promoted by a slight softening of the films at the temperatures in the nip.
  • the softening point can be adjusted by the content of plasticizers in the release films.
  • the films are made of an elastomer, they have a tensile strength measured in accordance with DIN EN ISO 527-1 in the range from 3 to 40 MPa, preferably 7 to 30 MPa.
  • the elongation at break according to DIN EN ISO 527-1 is at least 200%, preferably at least 400%.
  • the release films may be passed through the nip by unwinding the film from a roll and passing through the nip onto a second roll is wound up.
  • the release film can be passed behind the roller through a scraper or a cleaning bath.
  • the release films are each closed to form an endless belt, which allows continuous process control.
  • the release film can rest on the outer surface of the forming rollers at the peripheries of the forming roller recesses
  • a variant of the method is to lead one or both release films spaced from the nip to the forming rollers and z. B. to lead over adjustable guide rollers in the gap.
  • tensioning screws which are attached to the guide rollers also permit precise adjustment of the thickness of the film in the calendering gap and thus the specific influence on the ejection forces with which the shaped bodies are pressed out of the cavities of the shaping roller.
  • the invention also relates to a device with shaping means, which consist of two forming rollers, which have at least one recess for receiving an active substance-containing melt.
  • the device is characterized in that the depression comprises a release film which can be reversibly transferred from a rest position into a deflected position by introducing the active substance-containing melt into the depression.
  • the material of the release films may be selected from elastomers and / or water-insoluble thermoplastic polymers.
  • elastomers such as silicone elastomers, acryllyl rubber, polyester urethane rubber, brominated butyl rubber, polybutadiene, chlorinated butyl rubber, chlorinated polyethylene, epichlorohydrin homo- / copolymer, polychloroprene, sulfurized polyethylene, ethylene-acrylate rubber, ethylene Propylene terpolymer, ethylene-propylene copolymer, polyether-urethane rubber, ethylene-vinyl acetate copolymer, fluororubber, fluorosilicone rubber, hydrogenated nitrile rubber, butyl rubber, dimethylpolysiloxane, nitrile rubber (low, medium, high ACN content , Natural rubber, thioplast, polyfluorophosphazenes, polynorbonene, styrene-butadiene rubber, and carboxy-group containing nitrile rubbers or mixtures thereof.
  • silicone elastomers such as
  • silicones which are accepted as product-contacting materials in pharmaceutical production processes, for example silicones. These silicone materials can addition-crosslinking, condensation-curing or free-radical crosslinking.
  • polyolefins and polyolefin derivatives or copolymers for example polyethylene, polypropylene, polyisobutylene, poly-4-methylpentene and vinyl acetate, vinyl alcohol, acrylic or methacrylic copolymers
  • vinyl polymers eg polystyrene and polystyrene terpolymers and block polymers, for example copolymers of styrene, acrylonitrile and butadiene
  • polyvinyl chloride and copolymers for example copolymers of vinyl chloride and vinyl acetate, methacrylate or acrylonitrile
  • polyvinyl acetate polyvinyl alcohol, polyvinyl methyl ether
  • fluoropolymers such as polytetrafluoroethylene, polyvinyldiene fluoride, polyvinyl fluoride, Polyacrylates and methacrylates such as Polyacrylonitrile, polymethyl methacrylate
  • thermoplastic polymers whose softening point is above the temperature of the active substance-containing melt when it enters the calendering gap.
  • preference is given to guiding the film as an endless belt through the calendering gap, since this does not result in any film waste.
  • profiled foils e.g. Noppenfolien
  • geometries of the dosage forms can be further changed.
  • the preparation of the dosage forms is carried out starting from a mixture containing one or more active pharmaceutical ingredients and one or more auxiliaries and which is doughy or viscous by melting or softening at least one component and therefore extrudable.
  • polymers for example Homopolymers and copolymers of N-vinyl lactams, especially homopolymers and copolymers of N-vinyl pyrrolidone, e.g. As polyvinylpyrrolidone (PVP), copolymers of N-vinylpyrrolidone and vinyl acetate or vinyl propionate,
  • PVP polyvinylpyrrolidone
  • Cellulose esters and cellulose ethers in particular methylcellulose and ethylcellulose, hydroxyalkylcelluloses, in particular hydroxypropylcellulose, hydroxyalkylalkylcelluloses, in particular hydroxypropylmethylcellulose, cellulose phthalates or succinates, in particular cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose succinate or hydroxypropylmethylcellulose acetate succinate,
  • High molecular weight polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide,
  • Polyacrylates and polymethacrylates such as methacrylic acid / ethyl acrylate copolymers, methacrylic acid / methyl methacrylate copolymers, butyl methacrylate / 2-dimethylaminoethyl methacrylate copolymers, poly (hydroxyalkyl acrylates), poly (hydroxyalkyl methacrylates),
  • Vinyl acetate polymers such as copolymers of vinyl acetate and crotonic acid, partially hydrolyzed polyvinyl acetate (also referred to as partially saponified polyvinyl alcohol),
  • Oligo- and polysaccharides such as carrageenans, galactomannans and xanthans, or mixtures of one or more thereof.
  • homopolymers or copolymers of vinylpyrrolidone are particularly preferred, for.
  • VP N-vinylpyrrolidone
  • VA vinyl acetate
  • a copolymer of 60 wt .-% VP and 40 wt .-% VA a copolymer of 60 wt .-% VP and 40 wt .-% VA.
  • active substances are to be understood as meaning all substances having a desired physiological action on the human or animal body or plants. These are in particular pharmaceutical active ingredients.
  • the amount of active ingredient per unit dose can vary within wide limits. It is usually chosen so that it is sufficient to achieve the desired effect. Also drug combinations can be used.
  • Active substances within the meaning of the invention are also vitamins and minerals.
  • the vitamins include the vitamins of the A group, the B group, which in addition to B 1 , B 2 , B 6 and B 12 and nicotinic acid and nicotinamide and compounds with vitamin B properties are understood, such.
  • adenine As adenine, choline, pantothenic acid, biotin, adenylic acid, folic acid, orotic acid, pangamic acid, carnitine, p-aminobenzoic acid, myo-inositol and lipoic acid and vitamin C, vitamins of the D group, E group, F group, H group , I and J group, K group and P group.
  • Active substances within the meaning of the invention also include peptide therapeutics and proteins.
  • For plant treatment agents include, for. Vinclozolin, epoxiconazole and quinmerac.
  • the process according to the invention is suitable, for example, for processing the following active substances:
  • the mass may also include various optional adjuvants.
  • optional adjuvants are:
  • Plasticizers such.
  • the concentration of plasticizer if present, is generally 0.5 to 30, preferably 0.5 to 10,% by weight, based on the total weight of polymer and plasticizer.
  • the amount of plasticizer is advantageously at most 30% by weight, based on the total weight of polymer and plasticizer, in order to form storage-stable formulations and dosage forms, which do not show any cold flow, in the area of solid forms.
  • Sugar alcohols such as sorbitol, xylitol, mannitol, maltitol; or sugar alcohol derivatives such as isomalt or hydrogenated condensed Palatinose as described in DE 102 62 005.
  • Solubilizers such as sorbitan fatty acid esters, polyalkoxylated fatty acid esters, such as. B polyalkoxylated glycerides, polyalkoxylated sorbitan fatty acid esters or fatty acid esters of polyalkylene glycols; or polyalkoxylated ethers of fatty alcohols.
  • a fatty acid chain in these compounds usually comprises 8 to 22 carbon atoms.
  • the polyalkylene oxide blocks comprise on average from 4 to 50 alkylene oxide units, preferably ethylene oxide units, per molecule.
  • Suitable sorbitan fatty acid esters are sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan tristearate, sorbitan trioleate, sorbitan monostearate, sorbitan monolaurate or sorbitan monooleate.
  • Suitable polyalkoxylated sorbitan fatty acid esters include, for example, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan tristearate, polyoxyethylene (20) sorbitan trioleate, polyoxyethylene (4) sorbitan monostearate, polyoxyethylene (4 ) sorbitan monolaurate or polyoxyethylene (4) sorbitan monooleate.
  • Suitable polyalkoxylated glycerides are z. B. obtained by alkoxylation of natural or hydrogenated glycerides or by transesterification of natural or hydrogenated glycerides with polyalkylene glycols.
  • Commercial examples are Polyoxyethylenglycerolricinoleat-35, Polyoxyethylenglyceroltrihydroxystearat-40 (Cremophor® RH40, BASF AG) and polyalkoxylated glycerides as they are available under the trade names Gelucire® and Labrafil® from Gattefosse, z.
  • Gelucire® 44/14 (lauroyl-macrogol-32-glycerides prepared by transesterification of hydrogenated palm kernel oil with PEG 1500), Gelucire® 50/13 (stearoyl macrogol-32-glycerides prepared by transesterification of hydrogenated palm oil with PEG 1500 ) or Labrafil M1944 CS (oleoyl-macrogol-6-glycerides prepared by transesterification of apricot kernel oil with PEG 300).
  • a suitable fatty acid ester of polyalkylene glycols is e.g. B. PEG-660-hydroxystearic acid (polyglycol ester of 12-hydroxystearic acid (70 mol%) with 30 mol% ethylene glycol).
  • Suitable polyalkoxylated ethers of fatty alcohols are, for. Macrogol 6 cetyl stearyl ether or Macrogol 25 cetyl stearyl ether
  • Solubilizers are typically included in the powder mixture in an amount of 0.1 to 15% by weight, preferably 0.5 to 10% by weight.
  • Disintegrants such as crosslinked polyvinylpyrrolidone and crosslinked sodium carboxymethylcellulose.
  • Extenders or fillers such as lactose, cellulose, silicates or silica
  • Lubricants such as magnesium and calcium stearate, sodium stearyl fumarate,
  • Dyes such as azo dyes, organic or inorganic pigments or dyes of natural origin
  • Stabilizers such as antioxidants, light stabilizers, hydroperoxide destroyers, radical scavengers, stabilizers against microbial attack.
  • the components or a part of the components of the melt are mixed before heating to form a powder mixture.
  • the mixing of the components for powder mixing takes place in conventional mixers, such as plowshare mixers, shaker or free-fall mixers and the like.
  • the heating of the powder mixture takes place in a device customary for this purpose.
  • heatable extruders or kneaders such as mixing kneaders (eg ORP, CRP, AP, DTB from List or Reactotherm from Krauss-Maffei or Ko-Kneader from Buss), Doppelmulden kneaders (tray mixers) and die kneaders (Internal mixer) or rotor / stator systems (eg Dispax from IKA).
  • the residence time of the mass in the extruder is preferably less than 5 minutes, in particular less than 3 minutes.
  • twin-screw extruders rotating in the same direction or in opposite directions and optionally equipped with kneading disks.
  • co-rotating twin screw extruders are particularly preferred.
  • the feeding of the extruder or kneader takes place, depending on their design, continuously or discontinuously in the usual way.
  • the powder mixture is preferably in the free feed, z. B. be introduced via a differential dosing.
  • the pulverulent mixture of the polymer and the active ingredient is introduced at an inlet end into an elongated extruder housing; heats the mixture to obtain a melt; moves the melt through the extruder barrel to an exit end of the extruder barrel; and generates a sufficient back pressure in the Extruder housing, so that the melt emerges from an outlet end of the extruder housing as a coherent extrudate.
  • the resulting composition is then subjected to shaping according to the invention.
  • shaping according to the invention In this case, a variety of shapes, depending on the tool and type of molding, can be generated.
  • these forms can also be ground to powder and then compressed in the usual way to tablets.
  • tabletting aids such as colloidal silica, calcium hydrogen phosphate, lactose, microcrystalline cellulose, starch or magnesium stearate can be used.
  • the molding rolls usable in the invention for shaping the melt can be cooled or heated in a manner known per se, and the optimum surface temperature of the molding roll for the respective processing can be adjusted in this manner.
  • FIG. 1a shows a suitable apparatus 1 for carrying out the method according to the invention with counter-rotating forming rollers 2 and 3.
  • the forming rollers 2 and 3 have recesses 4 and 5 on their surface.
  • On the lateral surface of the forming rollers 2 and 3 is a release film 7.
  • the release film 7 is pressed in the nip in the wells 4 and 5. After leaving the nip, the portions of the melt 6 are removed from the mold.
  • FIG. 1 b shows an enlarged detail of the gap between the forming rollers 2 and 3 from FIG. 1 a and shows the separating film 7 in its rest position 8 or its deflected position 9.
  • Adjustable guide rollers 10 allow the separating films 7 to be guided at a distance from the forming rollers 2 and 3 outside the nip. Adjusted to the guide rollers 10 screws 11 and 12 (not shown in FIG. 2) allow the distance of the guide rollers 10 to vary and thus adjust the tension of the release film 7, when using elastic bands an accurate adjustment of the thickness of the release film 7 in the nip
  • a mixture containing 50% by weight of verapamil hydrochloride, 32% by weight of hydroxypropylcellulose (Klucel EF, Aqualon) and 18% by weight of hydroxypropyl methylcellulose (Methocel K4M; Colorcon) was used in a co-rotating twin-screw extruder at a screw speed of 80 U / min and a melt product temperature of 110 - 120 ° C extruded into a homogeneous extrudate melt.
  • the melt came directly after exiting the extruder head between a pair of counter-rotating mold rolls, the molding rolls each had recesses on their surface, with the help of which in the nip from the melt directly tablets could be formed.
  • the forming rolls were coated with an annular elastomeric film which had been cut out of the gum area of a rubber glove (Duo-Nit Co., material: latex mix, film thickness: 0.4 mm).
  • This elastomeric ring had a slightly smaller diameter than the forming rolls in the unstretched state and therefore sat firmly on the forming roll surface in a slightly stretched state.
  • a mold roll temperature of 10 ° C could be produced directly from the drug-containing melt direct elongated tablets of about 1000 mg in weight. There were no problems with melt sticking in the cavities of the forming rolls.
  • Example 2 The procedure was as in Example 1, but without using the elastomeric film on the rollers. The melt adhered too much to the calender roll surfaces, i. a demolding of the tablets did not succeed.
  • Example 2 The procedure was as described in Example 1, but with a mixture consisting of 50 wt .-% verapamil hydrochloride, 40 wt .-% hydroxypropyl cellulose (Klucel EF, Aqualon) and 10 wt .-% hydroxypropyl methylcellulose (Methocel K100M; Colorcon ).
  • the calendering was carried out with an elastomer ring (elastomeric film from the cuff area of a rubber glove, Berner, cytostatic rubber glove Bl-4021, material: natural latex, film thickness: 0.26 mm). There were no problems with melt sticking in the cavities of the forming rolls.
  • Example 3 The procedure was as in Example 3, but without the use of the rollers on the elastomeric film. The melt adhered too strongly to the calender roll surfaces, ie a demolding of the tablets did not succeed.
  • Example 2 The procedure was as described in Example 1, but with a mixture consisting of 55 wt .-% hydroxypropyl cellulose (Klucel EF, Aqualon) and 45 wt .-% mannitol (Merck).
  • the calendering was carried out using an elastomer ring (elastomeric film from the cuff area of a rubber glove, Reichelt Chemie-Technik, Thomastat-HSR-2020 15 MIL black gloves, material: soft plastic, film thickness: 0.15 mm). There were no problems with melt sticking in the cavities of the forming rolls.
  • Example 5 The procedure was as in Example 5, but without the use of the rollers on the elastomeric film. The melt adhered too much to the calender roll surfaces, i. a demolding of the tablets did not succeed.
  • the melt came directly after exiting the extruder head between a pair of counter-rotating mold rolls, the molding rolls each had depressions on their surface, with the help of which in the nip from the melt directly tablets could be formed.
  • the tablets were readily demoulded using the elastomeric film specified in Example 1. There were no problems with melt sticking in the cavities of the forming rolls.
  • Example 7 The procedure was as in Example 7, but without the use of the rollers on the elastomeric film. The melt adhered too much to the calender roll surfaces, i. a demolding of the tablets did not succeed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
EP05003457A 2005-02-17 2005-02-17 Production de formes posologiques à partir de substances actives fondues Withdrawn EP1693045A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP05003457A EP1693045A1 (fr) 2005-02-17 2005-02-17 Production de formes posologiques à partir de substances actives fondues
JP2007555537A JP2008529852A (ja) 2005-02-17 2006-02-17 作用物質含有溶融物からなる投与形の製造
PCT/EP2006/001475 WO2006087218A1 (fr) 2005-02-17 2006-02-17 Production de formes de dosage a partir de matieres fondues contenant un principe actif
US11/884,521 US20090050262A1 (en) 2005-02-17 2006-02-17 Production of Dosing Molds from Active Substance-Containing Melts
ES06707060.7T ES2445828T3 (es) 2005-02-17 2006-02-17 Obtención de formas de dosificación a partir de fusiones que contienen productos activos
DK06707060.7T DK1848394T3 (da) 2005-02-17 2006-02-17 Fremstilling af doseringsformer af smeltemasser, der indeholder aktive bestanddele
EP06707060.7A EP1848394B1 (fr) 2005-02-17 2006-02-17 Production de formes posologiques à partir de substances actives fondues
CA2598168A CA2598168C (fr) 2005-02-17 2006-02-17 Production de formes de dosage a partir de matieres fondues contenant un principe actif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05003457A EP1693045A1 (fr) 2005-02-17 2005-02-17 Production de formes posologiques à partir de substances actives fondues

Publications (1)

Publication Number Publication Date
EP1693045A1 true EP1693045A1 (fr) 2006-08-23

Family

ID=34933806

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05003457A Withdrawn EP1693045A1 (fr) 2005-02-17 2005-02-17 Production de formes posologiques à partir de substances actives fondues
EP06707060.7A Active EP1848394B1 (fr) 2005-02-17 2006-02-17 Production de formes posologiques à partir de substances actives fondues

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP06707060.7A Active EP1848394B1 (fr) 2005-02-17 2006-02-17 Production de formes posologiques à partir de substances actives fondues

Country Status (7)

Country Link
US (1) US20090050262A1 (fr)
EP (2) EP1693045A1 (fr)
JP (1) JP2008529852A (fr)
CA (1) CA2598168C (fr)
DK (1) DK1848394T3 (fr)
ES (1) ES2445828T3 (fr)
WO (1) WO2006087218A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108309796A (zh) * 2018-01-17 2018-07-24 刘雅文 一种压缩中药饮片及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
TW200950776A (en) * 2008-01-24 2009-12-16 Abbott Gmbh & Co Kg Abuse resistant melt extruded formulation having reduced alcohol interaction
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
KR102585933B1 (ko) * 2022-09-21 2023-10-06 주식회사 태성공영 구형 성형체 제조장치
CN117698024B (zh) * 2023-12-18 2024-06-25 青岛环球输送带有限公司 一种节能式橡胶硫化机

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5722900A (en) * 1980-07-12 1982-02-05 Kurosaki Refract Co Ltd Pocket structure in roll or the like for briquetting machine
JPH0263699A (ja) * 1988-08-29 1990-03-02 Fuji Paudaru Kk 圧縮造粒装置
EP0358105A2 (fr) 1988-09-07 1990-03-14 BASF Aktiengesellschaft Procédé et dispositif de fabrication continue de formes pharmaceutiques dures
SU1600670A2 (ru) * 1987-12-03 1990-10-23 Кемеровский технологический институт пищевой промышленности Устройство дл формовани конфетных масс
DE4446467A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von linsenförmigen Tabletten durch Schmelzkalandrierung
WO1996019963A1 (fr) 1994-12-23 1996-07-04 Basf Aktiengesellschaft Procede de fabrication de comprimes enrobes
WO1997007786A2 (fr) 1995-08-25 1997-03-06 Basf Aktiengesellschaft Utilisation de lipides comme adjuvants dans la fabrication de formes medicamenteuses solides selon le procede d'extrusion de matiere fondue
DE10262005A1 (de) 2002-09-11 2004-03-25 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Kondensierte Paltinose in hydrierter Form

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1824158C (ru) * 1991-03-11 1993-06-30 Кемеровский технологический институт пищевой промышленности Устройство дл формовани конфетных масс

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5722900A (en) * 1980-07-12 1982-02-05 Kurosaki Refract Co Ltd Pocket structure in roll or the like for briquetting machine
SU1600670A2 (ru) * 1987-12-03 1990-10-23 Кемеровский технологический институт пищевой промышленности Устройство дл формовани конфетных масс
JPH0263699A (ja) * 1988-08-29 1990-03-02 Fuji Paudaru Kk 圧縮造粒装置
EP0358105A2 (fr) 1988-09-07 1990-03-14 BASF Aktiengesellschaft Procédé et dispositif de fabrication continue de formes pharmaceutiques dures
DE4446467A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von linsenförmigen Tabletten durch Schmelzkalandrierung
WO1996019963A1 (fr) 1994-12-23 1996-07-04 Basf Aktiengesellschaft Procede de fabrication de comprimes enrobes
WO1997007786A2 (fr) 1995-08-25 1997-03-06 Basf Aktiengesellschaft Utilisation de lipides comme adjuvants dans la fabrication de formes medicamenteuses solides selon le procede d'extrusion de matiere fondue
DE10262005A1 (de) 2002-09-11 2004-03-25 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Kondensierte Paltinose in hydrierter Form

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9494, 21 December 1994 Derwent World Patents Index; Class 44, AN 1994-356500 *
PATENT ABSTRACTS OF JAPAN vol. 006, no. 086 (M - 131) 25 May 1982 (1982-05-25) *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 237 (M - 0976) 21 May 1990 (1990-05-21) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108309796A (zh) * 2018-01-17 2018-07-24 刘雅文 一种压缩中药饮片及其制备方法

Also Published As

Publication number Publication date
WO2006087218A1 (fr) 2006-08-24
CA2598168A1 (fr) 2006-08-24
ES2445828T3 (es) 2014-03-05
EP1848394B1 (fr) 2013-10-09
CA2598168C (fr) 2014-09-23
US20090050262A1 (en) 2009-02-26
EP1848394A1 (fr) 2007-10-31
JP2008529852A (ja) 2008-08-07
DK1848394T3 (da) 2014-01-20

Similar Documents

Publication Publication Date Title
EP0864324B1 (fr) Méthode pour la production de formes pharmaceutiques solides combinées
EP0857062B1 (fr) Procede de preparation de formes galeniques solides multicouches pour administration orale ou rectale
EP0993828B1 (fr) Procédé pour produire des formes de dosage solides enrobées
EP0799012B1 (fr) Procede de fabrication de comprimes enrobes
EP0998920B1 (fr) Procede de production de formes solides de dosage
EP2114375B1 (fr) Agent d'enrobage sous forme de film, formé de particules à dispersion rapide, à base de copolymères greffés de polyvinylalcool-polyéther
EP0820753A2 (fr) Procédé de fabrication de produits pharmaceutiques solides
EP1848394B1 (fr) Production de formes posologiques à partir de substances actives fondues
EP1143910B1 (fr) Procede et dispositif pour produire differentes formes galeniques solides
EP1556012B1 (fr) Production de formes galeniques solides au moyen d'un excipient non thermoplastique reticule
AU705657B2 (en) Molding belt calender
EP1748762B1 (fr) Forme de dosage obtensible à partir d'un mélange de poudres contenant un pigment inorganique
EP0931552A2 (fr) Procédé de préparation de formes solides de dosage
WO1997015291A1 (fr) Procede de preparation de formes galeniques solides
WO2008080773A1 (fr) Procédé de production de formes galéniques solides contenant des copolymères greffés
EP0859602A1 (fr) Procede de preparation de formes galeniques solides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

AKX Designation fees paid
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070224

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566